2007
DOI: 10.1038/sj.bmt.1705754
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: Seventy-one allograft recipients receiving voriconazole, in whom complete clinical, microbiologic and pharmacokinetic data were available, were studied to determine the efficacy of voriconazole in preventing fungal infections. The length of voriconazole therapy was 6-956 days (median 133). The total number of patient-days on voriconazole was 13 805 (B38 years). A total of 10 fungal infections were seen in patients on voriconazole (18% actuarial probability at 1 year): Candida glabrataand Mucor (n ¼ 1). Two of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

7
171
1
1

Year Published

2007
2007
2019
2019

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 217 publications
(180 citation statements)
references
References 24 publications
7
171
1
1
Order By: Relevance
“…[31][32][33][34][35][36][37] However, it is still to be decided which is the best choice of treatment. Posaconazole seems to be better when compared to others, since not only is it active in vitro against a wide range of yeasts (including candida species) and molds (including aspergillus species, zygomycetes, and fusarium species) but also appears to have an acceptable adverse-event profile and it is well tolerated.…”
Section: Treatments and Guidelinesmentioning
confidence: 99%
“…[31][32][33][34][35][36][37] However, it is still to be decided which is the best choice of treatment. Posaconazole seems to be better when compared to others, since not only is it active in vitro against a wide range of yeasts (including candida species) and molds (including aspergillus species, zygomycetes, and fusarium species) but also appears to have an acceptable adverse-event profile and it is well tolerated.…”
Section: Treatments and Guidelinesmentioning
confidence: 99%
“…Breakthrough invasive mucormycosis has been observed in patients receiving voriconazole or echinocandins (Kontoyiannis et al, 2005;Trifilio et al, 2007), and also for posaconazole (Kang et al, 2015;Mousset et al, 2010), showing reduced sensitivity of some Mucorales species (Almyroudis et al, 2007).…”
Section: Introductionmentioning
confidence: 99%
“…Voriconazole is a triazole drug with a broad spectrum of activity, and is one of the agents used for fungal prophylaxis after allogeneic HSCT. 7,8 Voriconazole is a competitive inhibitor for the cytochrome P450 3A4, 2C9 and 2C19 isosenzyme systems. 9,10 Predictably, numerous serious drug interactions have been described for voriconazole when combined with other drugs metabolized through these systems, including tacrolimus.…”
Section: Introductionmentioning
confidence: 99%